Next Article in Journal
Considerations for Newborn Screening for Critical Congenital Heart Disease in Low- and Middle-Income Countries
Next Article in Special Issue
Establishing Pompe Disease Newborn Screening: The Role of Industry
Previous Article in Journal
It All Depends What You Count—The Importance of Definitions in Evaluation of CF Screening Performance
Previous Article in Special Issue
Second Tier Molecular Genetic Testing in Newborn Screening for Pompe Disease: Landscape and Challenges
Open AccessArticle

Expanding Newborn Screening for Pompe Disease in the United States: The NewSTEPs New Disorders Implementation Project, a Resource for New Disorder Implementation

1
Association of Public Health Laboratories, Silver Spring, MD 20910, USA
2
Center for Public Health Innovation, Littleton, CO 80120, USA
3
Colorado School of Public Health, Department of Epidemiology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA
*
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2020, 6(2), 48; https://doi.org/10.3390/ijns6020048
Received: 12 May 2020 / Revised: 6 June 2020 / Accepted: 8 June 2020 / Published: 11 June 2020
(This article belongs to the Special Issue Newborn Screening for Pompe Disease)
Public health programs in the United States screen more than four million babies each year for at least 30 genetic disorders. The Health and Human Services (HHS) Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) recommends the disorders for state newborn screening (NBS) programs to screen. ACHDNC updated the Recommended Uniform Screening Panel (RUSP) to include Pompe disease in March 2015. To support the expansion of screening for Pompe disease, the Association of Public Health Laboratories (APHL) proposed the Newborn Screening Technical assistance and Evaluation Program (NewSTEPs) New Disorders Implementation Project, funded by the HHS’ Health Resources and Services Administration (HRSA) Maternal and Child Health Bureau (MCHB). Through this project, APHL provided financial support to 15 state NBS programs to enable full implementation of screening for Pompe disease. As of April 27, 2020, nine of the 15 programs had fully implemented Pompe disease newborn screening and six programs are currently pursuing implementation. This article will discuss how states advanced to statewide implementation of screening for Pompe disease, the challenges associated with implementing screening for this condition, the lessons learned during the project, and recommendations for implementing screening for Pompe disease. View Full-Text
Keywords: newborn screening; Pompe disease; new disorders implementation newborn screening; Pompe disease; new disorders implementation
Show Figures

Figure 1

MDPI and ACS Style

Hale, K.; Kellar-Guenther, Y.; McKasson, S.; Singh, S.; Ojodu, J. Expanding Newborn Screening for Pompe Disease in the United States: The NewSTEPs New Disorders Implementation Project, a Resource for New Disorder Implementation. Int. J. Neonatal Screen. 2020, 6, 48.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop